Other treatment options, like hypomethylating drugs and BCL2 inhibitors, are commonly used to treat IDH-mutant hematologic malignancies like acute myeloid leukemia (AML) but have not been formally studied in the treatment of IDH-mutant gliomas. This evidence concerns the gene IDH2 and central nervous system cancer.